organ-on-a-chip

organ-on-a-chip. An organ-on-a-chip is a multi-channel 3-D microfluidic cell culture chip that simulates the activities, mechanics, and physiological response of entire organs and organ systems. This technology represents a convergence of tissue engineering, microfabrication, and systems biology, creating a type of microphysiological system. It is primarily used in biomedical research and drug development to model human physiology in vitro, offering a potential alternative to traditional animal testing.

Overview

The fundamental concept emerged from pioneering work at the Wyss Institute for Biologically Inspired Engineering at Harvard University, led by researchers like Donald Ingber and Geraldine Hamilton. These devices are designed to replicate the minimal functional unit of a living organ by culturing living human cells within continuously perfused, micrometer-sized chambers. This approach allows for the recreation of tissue-tissue interfaces, mechanical forces like peristalsis or cyclic strain, and the precise control of the biochemical microenvironment. The technology gained significant attention following a landmark 2010 publication on a lung-on-a-chip model in the journal Science. Major entities advancing the field include companies like Emulate, Inc., TissUse, and Hesperos.

Design and fabrication

The architecture typically involves bonding layers of a transparent, biocompatible polymer like polydimethylsiloxane (PDMS) to form hollow microchannels. Fabrication employs techniques borrowed from the semiconductor industry, such as soft lithography and photolithography, to create these precise structures. A critical design feature is the inclusion of a porous membrane, often coated with extracellular matrix proteins like collagen or fibronectin, which separates channels to co-culture different cell types. Integrated microfluidic pumps and valves control the flow of culture media, mimicking blood flow and enabling the delivery of nutrients, drugs, or immune cells. Sensors can be incorporated to measure transepithelial electrical resistance or pH in real-time.

Types and applications

Numerous organ-specific models have been developed, each targeting a key physiological function. A liver-on-a-chip is used to study metabolism and drug-induced liver injury, while a kidney-on-a-chip models the glomerular filtration barrier and nephrotoxicity. Other prominent types include heart-on-a-chip for cardiotoxicity screening, intestine-on-a-chip for nutrient absorption studies, and blood-brain barrier-on-a-chip for neuropharmacology research. Applications extend beyond pharmaceutical companies like Pfizer and Johnson & Johnson; they are used in toxicology testing by agencies such as the Environmental Protection Agency, modeling infectious diseases like COVID-19, and studying cancer metastasis in platforms developed by institutions like the Massachusetts Institute of Technology.

Advantages and limitations

Primary advantages include the potential to increase the predictive accuracy for human responses compared to animal models, as demonstrated in studies funded by the National Institutes of Health and the Food and Drug Administration. They enable real-time, high-resolution imaging and analysis of cellular behavior, reduce reagent costs, and can be linked to form human-on-a-chip systems. However, significant limitations remain. The simplicity of these systems often fails to capture the full cellular complexity of an organ. Challenges include the limited longevity of cell cultures, the difficulty of scaling production for high-throughput screening, and the use of materials like PDMS that can absorb small molecules, potentially skewing drug metabolism data.

Future directions

Future research aims to enhance biological fidelity by incorporating patient-derived stem cells, immune system components, and microbiome elements. A major goal is the development of standardized, interconnected multi-organ chips that can simulate systemic interactions for studying pharmacokinetics and complex diseases. Initiatives like the Microphysiological Systems (MPS) Program at the National Center for Advancing Translational Sciences are driving this integration. Further innovation is expected in automation, data analysis using machine learning, and the creation of personalized medicine platforms to tailor treatments based on an individual's specific chip response.

Category:Biotechnology Category:Microtechnology Category:Medical research